Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1980 3
1983 1
1993 3
1996 1
1997 3
1999 5
2001 2
2002 1
2004 6
2006 1
2007 3
2008 6
2009 2
2010 9
2011 13
2012 11
2013 19
2014 8
2015 14
2016 25
2017 37
2018 33
2019 21
2020 39
2021 30
2022 21
2023 16
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 27688475

283 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging.
Jager A, de Vries EGE, der Houven van Oordt CWM, Neven P, Venema CM, Glaudemans AWJM, Wang Y, Bagley RG, Conlan MG, Aftimos P. Jager A, et al. Breast Cancer Res. 2020 Sep 11;22(1):97. doi: 10.1186/s13058-020-01333-3. Breast Cancer Res. 2020. PMID: 32912274 Free PMC article. Clinical Trial.
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential significant biomarkers.
Park JH, Kang MJ, Ahn JH, Kim JE, Jung KH, Gong G, Lee HJ, Son BH, Ahn SH, Kim HH, Shin HJ, Moon DH, Kim SB. Park JH, et al. Cancer Chemother Pharmacol. 2016 Oct;78(4):685-95. doi: 10.1007/s00280-016-3107-6. Epub 2016 Aug 4. Cancer Chemother Pharmacol. 2016. PMID: 27491481 Clinical Trial.
The Predictive Value of Early Changes in 18 F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
He M, Liu C, Shi Q, Sun Y, Zhang Y, Xu X, Yuan H, Zhang Y, Liu Y, Liu G, Di G, Yang Z, Wang Z, Shao Z. He M, et al. Oncologist. 2020 Nov;25(11):927-936. doi: 10.1634/theoncologist.2019-0561. Epub 2020 Apr 28. Oncologist. 2020. PMID: 32272493 Free PMC article.
Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Ueda S, Tsuda H, Saeki T, Omata J, Osaki A, Shigekawa T, Ishida J, Tamura K, Abe Y, Moriya T, Yamamoto J. Ueda S, et al. Breast Cancer. 2011 Oct;18(4):299-308. doi: 10.1007/s12282-010-0212-y. Epub 2010 Jul 9. Breast Cancer. 2011. PMID: 20617404 Clinical Trial.
283 results